Navigation

Skiplink Navigation

Main Features

Personalised medicine Roche develops tool for one-day cancer diagnosis

breast cancer xray

Some 15-20% of women diagnosed with breast cancer are HER2 positive.

(Keystone)

As part of its personalised medicine strategy, Swiss pharmaceutical company Roche has launched a diagnostic tool for breast and gastric cancer patients with specific HER2 genetic mutations.

The new VENTANA HER2 companion diagnostic assayexternal link was launched on Tuesday and promises to identify more quickly and effectively the HER2 biomarker in breast and gastric cancer to manage the diseases with targeted therapies.

HER2-positive breast cancer is considered more aggressiveexternal link than many other types of breast cancer as it is less likely to be sensitive to hormone therapy.

Newsletter subscription for Multinationals

subscription form for multinationals

Subscribe to our newsletter to keep informed of the latest trends affecting multinationals.


The VENTANA assay is designed to be completed within a day, giving clinicians the ability to get results back quicker than the other common methods for confirming HER2. Results can be read using light microscopy, eliminating the need for a specialised fluorescence microscope.

Holy grail

The development of companion diagnostics is an important part of Roche’s focus on personalised medicineexternal link. This is considered the holy grail of medicine whereby targeted treatments are employed based on the unique characteristics of each patient’s disease rather than a one-size-fits-all approach.

In the cancer treatment arena, pharma companies are shifting from the traditional way of treating cancer focused on tumour location to treating the mutation directly, offering more opportunities for precision.

Latest cancer research

Meanwhile, researchers from the University of Zurichexternal link have created an innovative method using ultraviolet (UV) light to synthesise radioactive drugs and diagnostic agents to fight cancer.

Radioactive antibodies that target cancer cells are used for medical diagnostics with PET (positron emission tomography) imaging or for targeted radioimmunotherapy.

Conventional methods for radiolabelling proteins take much longer and are difficult to automate. The method developed by the University of Zurich researchers uses UV light to produce radiolabelled antibodies in a mere 15 minutes that can be used for cancer imaging or therapy.

A patent application for the new procedure has been submitted and there are plans for commercial development.

end of infobox

WEF19 - Future of Health The pharma holy grail: drugs for you, designed by you

In the age of sensors, wearables, and artificial intelligence (AI), almost everything can be customised for the individual.

Keystone-SDA/jdp

Neuer Inhalt

Horizontal Line


SWI swissinfo.ch on Instagram

SWI swissinfo.ch on Instagram

SWI swissinfo.ch on Instagram

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.









Click here to see more newsletters